Segment & Geographic Data
API & CSV Delivery
Novabridge Biosciences's Business Segments
Novabridge Biosciences's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
1
Largest Segment
Oncology
Total Revenue
$ 1
Regions Reported
-
Annual Results
Revenue Share by Reportable Segment - FY2023
- Oncology100%
Revenue by Reportable Segment - FY2023
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Oncology | $ 1 | 100% |
Revenue by Product & Service Category - FY2023
- Licensing and Collaboration100%
Revenue by Product & Service Category - FY2023
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Licensing and Collaboration | $ 1 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Novabridge Biosciences
The registrant operates in China and is subject to evolving and complex PRC laws and regulations related to data privacy, cybersecurity, and scientific data management. Compliance includes restrictions on outbound data transfers, particularly involving scientific data that may contain state secrets. Noncompliance may result in government penalties, operational suspensions, and reputational harm. The PRC legal system's uncertainties and regional variations in enforcement present challenges to the registrant's operations and legal protections. The company also faces risks from geopolitical tensions between the United States and China, which could affect trade policies, tariffs, and international cooperation. These tensions may impact the registrant's drug development activities, including hiring, raw material import and export, and market access. Although the company has not yet commercialized its drug candidates, these external factors could materially and adversely affect its business, financial condition, and prospects. Additionally, the registrant acknowledges limitations on U.S. authorities' ability to enforce securities laws against it or its directors due to jurisdictional and legal obstacles.